ESMO Breast 2024 | ACROSS-TROP2: identifying predictive biomarkers of SG in HR+/HER2- breast cancer

Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, gives an overview of the rationale and trial design of the Phase II ACROSS-TROP2 study (NCT06236269), which aims to elucidate predictive biomarkers of sacituzumab govitecan (SG) and to understand resistance mechanisms in patients with HR+/HER2- advanced or metastatic breast cancer. The primary endpoint includes changes in the long term efficacy outcomes in tumor samples, and secondary endpoints include overall response rate, progression-free survival, duration of response, time to response, safety, and tolerability. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.